Background: A major requirement for malaria elimination is the development of transmission-blocking interventions.
Background
Among the actions required for malaria elimination, blocking the transmission of Plasmodium parasites from human to mosquitoes is critical [1] . Passage through the vector is an obligatory step for the parasite to continue its life cycle and it relies exclusively on the most mature forms of the sexual stages, stage V gametocytes. Mosquito feeding assays remain the gold standard to evaluate transmission-blocking strategies but require resourceintensive techniques. To circumvent these technical difficulties, several in vitro transmission-blocking bioassays targeting the sexual stages of the parasite have been described with different endpoints and various interpretative values [2, 3] . Although the outputs of these in vitro assays are difficult to transpose in vivo, the most clinically relevant assay should be able to evaluate the ability of a compound to either kill stage V gametocytes (viability assay) or inhibit their ability to differentiate into later mosquito stages (functional maturity assay). It is possible to induce in vitro gamete formation from Plasmodium falciparum male and female gametocytes where male gametocytes undergo major differentiation leading to the production of eight mobile gametes, by a process called exflagellation, which is easily observed visually.
Currently, the majority of P. falciparum in vitro transmission-blocking studies use a handful of reference laboratory strains, isolated decades ago. While these strains are useful to normalize high throughput screenings, results should be verified on natural parasites that have been selected after years of multiple drug exposures and hence are likely to display differential drug responses compared to reference strains. In addition, it is well known that gametocyte production capacity is lost over time of in vitro culture [2, 4] . Laboratories must therefore rely on precious stocks of cryopreserved isolates with minimal passage since in culture. Adaptation of P. falciparum isolates from patients to in vitro blood-stage culture is routinely performed. Studies describing the use of field isolates for in vitro gametocyte cultures have been published in the early 1980s and have led to the selection of the current reference strains [4] [5] [6] [7] [8] . Nowadays using circulating parasites after culture adaptation for transmissionblocking assay is rarely performed. Some studies have shown that they can be used in gametocyte viability assay [9] or for experimental infections of mosquitoes [10] , however their use for exflagellation-blocking bioassays, reporting in vitro functional maturity of gametocytes has not been reported yet. A requirement for their use in such assay is to be able to produce functional gametocytes in high enough number to be meaningful in a bioassay.
The objective of the work presented here was therefore to determine if culture-adapted field isolates could be used for recently developed in vitro exflagellationblocking bioassays [11] .
Methods

Reference strain and field isolates
The P. falciparum South American chloroquine-resistant strain 7G8 (MRA-926) has been obtained from the MR4. Plasmodium falciparum isolates were collected from monoinfected patients seeking treatment in 2013 in French Guiana (Q206 and Q188) and in 2014 in Cambodia (6831 and 6836).
In vitro culture adaptation
Culture adaptation of isolates was performed using standard protocols [12, 13] . Briefly, after removal of plasma, the red blood cell (RBC) pellet was washed three times in RPMI 1640 supplemented with gentamicin (Gibco-Life Technologies SAS, France) and placed in culture medium (RPMI 1640, 0.5 % AlbuMAX II (Gibco-Life Technologies SAS, France), 2 % decomplemented human plasma) at 4 % haematocrit at 37°C in 5 or 10 % O 2 , 5 % CO 2 , rest of N 2 atmosphere. Parasitaemia was checked daily and kept below 2 % by dilutions with fresh RBC and medium. Field isolates were considered adapted to in vitro conditions after three weeks of uninterrupted culture. After culture adaptation, asexual blood-stage sensitivity to anti-malarials was determined using the [ 3 H]-hypoxanthine incorporation assay [14] .
In vitro gametocyte production and maturation
Gametocyte cultures were performed following published protocols [2, 11] . Briefly, asexual cultures with a parasitaemia of~5 % were used to seed gametocyte cultures at 0.5-1 % parasitaemia and 4 % haematocrit under 5 or 10 % O 2 , 5 % CO 2 , rest of N 2 atmosphere. Culture medium (RPMI medium with 25 mM HEPES, 50 mg/L hypoxanthine, 2 g/L sodium bicarbonate, 10 % human serum) was replaced daily but without any further addition of RBCs and critically, temperature was maintained at all time at 37°C.
Gametocytogenesis was evaluated morphologically using Giemsa-stained blood films. Stage V male gametocyte functional maturity was assessed by observation of exflagellation in wet preparation under bright-field microscope. A 30-μL aliquot of gametocyte culture was briefly centrifuged, the cell pellet was resuspended in 15 μL of ookinete medium (RPMI medium with 25 mM HEPES, 50 mg/L hypoxanthine, 2 g/L sodium bicarbonate, 100 μM xanthurenic acid, 10 % human serum) and then introduced into a chamber of a FastRead disposable haemocytometer slide (Immune Systems). Exflagellation centres were observed at 10 × or 20 × magnification.
Exflagellation-blocking bioassay
Exflagellation-blocking assays were performed according to published protocols [11] . Assays were performed using gametocyte cultures providing high enough exflagellation centres for meaningful measures (>30 in five 10 × microscopy fields).
To show the suitability of field isolates for exflagellationblocking assays, the activity of 1 μM of dihydroartemisinin (DHA), methylene blue (MeBlue) and chloroquine (CQ) was evaluated. Assays were carried out in 1.5-mL tubes containing 170 μL of gametocyte culture medium with 1 μM of drugs dissolved in either DMSO or methanol. Thirty μL of stage V mature gametocyte was dispensed into each assay tube. Tubes were then placed into a 37°C incubator. After 24 h, exflagellation was induced by temperature drop to 25°C and replacing culture medium with ookinete medium. The number of exflagellation centres were recorded and compared to controls (DMSO or methanol). Activity was expressed as percentage of exflagellation inhibition compared to controls.
Results
The protocols were first optimized by using the South American isolates prior to being verified with the Southeast Asian isolates. Gametocyte development was straightforward at the first attempt. Initially however, although stage V gametocytes were clearly identified in the cultures, no exflagellation was observed. This suggests that bioassays with a read-out based only on morphological development of gametocytes do not report on their onward functional viability, therefore they may be underpowered. As already observed by others [2, 4] , the age of uninfected RBC when initiating the gametocyte culture was a critical factor for successful maturation: RBC stored at 4°C more than~two to 3 days rapidly compromise maturation. Additionally, variability in human serum was found also to be a critical point for gametocyte maturation, so pools from different donors of serum were used when possible. Using fresh uninfected RBC, fully mature gametocytes capable of exflagellation were generated for all isolates. For all isolates and 7G8, gametocyte development time was similar and maturity peaked at~16-18 days of culture, slightly longer than what is usually reported for 3D7,~12-14 days (Fig. 1) [2, 11] .
It is important to note that all the experiments using 7G8 and the South American isolates were performed in a different laboratory (Institut Pasteur de la Guyane, Cayenne) than those using the Cambodian isolates (Institut Pasteur du Cambodge, Phnom Penh) showing good reproducibility in the protocols that can be easily implemented in laboratories doing P. falciparum in vitro culture adaptation.
Exflagellation is a time-dependent process [15] . Within 20 min after induction, for all field isolates and the reference strain 7G8, a plateau is reached allowing consistent measurements for~10 min (Fig. 2) . This is similar to what has previously been observed with 3D7 [11] .
Although the patterns of gametocyte development and time for exflagellation are similar for all isolates and laboratory strains, there are variations in the amount of exflagellation centres from one isolate to another (see Additional file 1) as already observed by others [4] . For example, in French Guiana, the isolate Q206 consistently gave higher number of exflagellation than Q188. Nevertheless, for all the isolates, using gametocyte cultures at maturity, the numbers of exflagellation centres obtained were high enough to allow significant measures in exflagellation-blocking bioassay (from~35 to >100, see Additional file 1).
Based on those observations, a previously described exflagellation-blocking protocol was adapted to the four field isolates and 7G8 [11] . Exflagellation centres were recorded between 20 and 30 min after induction of 18 days-old gametocyte cultures. As a proof-of-concept, the activity of DHA and MeBlue was evaluated as both compounds have been previously reported to block exflagellation of 3D7 [11] . As negative control, CQ was used on a sub-set of the strains [16] . Mature gametocytes were incubated 24 h in presence of 1 μM of each drug before exflagellation was induced. All isolates responded similarly to the compounds with 1 μM DHA giving 78-99 % inhibition and consistently near total inhibition with 1 μM of MeBlue ( Table 1) . As expected, CQ had no effect on exflagellation in any isolate tested. Expressed as a percentage of inhibition compared to the drug-free control (mean ± SEM, n = 3)
